News | July 03, 2024
Avallano appoints Michael A. Ibara as Chief Strategy Officer
Ibara will drive AI-powered clinical research innovation
Ibara will drive AI-powered clinical research innovation
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Subscribe To Our Newsletter & Stay Updated
